Ventricular Tachycardia

Ventricular Tachycardia — scientific infographic poster

Table of Contents

  1. What Ventricular Tachycardia Is
  2. Types of VT: Monomorphic vs Polymorphic
  3. Sustained vs Non-Sustained VT
  4. Wide Complex Tachycardia: VT vs SVT
  5. Causes and Underlying Conditions
  6. Acute Management: Stable and Unstable VT
  7. Long-Term Treatment: ICD and Catheter Ablation
  8. ICD for Primary and Secondary Prevention
  9. Special Syndromes: Long-QT, Brugada, and CPVT
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What Ventricular Tachycardia Is

Ventricular tachycardia (VT) is a fast heart rhythm (≥3 consecutive beats at a rate of ≥100–120 beats per minute, bpm) that originates in the ventricles rather than the normal pacemaker system. Because the electrical signal starts in the muscular walls of the ventricles and spreads abnormally, each beat looks wide and distorted on the electrocardiogram (ECG) — the QRS complex is typically >120 milliseconds — and the heart pumps less efficiently.

VT ranges from brief, asymptomatic runs that most people never know about, to life-threatening sustained rhythms that can cause cardiac arrest within minutes. Understanding VT requires knowing its two critical dimensions: morphology (what does each beat look like?) and duration (how long does the episode last?). These two axes together determine risk and treatment.

Back to Table of Contents

Types of VT: Monomorphic vs Polymorphic

The shape of the QRS complex on the electrocardiogram is the first and most important diagnostic split:

Monomorphic VT

Every beat has the same QRS shape — each one looks identical to the last. This uniformity means a single, stable re-entry circuit is firing repeatedly from the same anatomical location. The most common setting is scar tissue from a prior heart attack (myocardial infarction). Scar does not conduct electricity; healthy tissue bordering the scar creates a slow conduction corridor (isthmus) that allows the electrical impulse to circle continuously. This is called scar-related re-entry.

Monomorphic VT also occurs in non-ischemic cardiomyopathies (dilated, hypertrophic, arrhythmogenic right ventricular cardiomyopathy/ARVC), sarcoidosis, and Chagas disease — wherever myocardial fibrosis creates anatomical substrate for re-entry.

Polymorphic VT

The QRS morphology changes beat to beat — each one looks different. This means the activation sequence is constantly shifting, which signals a more unstable and dangerous process. Common causes include:

Back to Table of Contents

Sustained vs Non-Sustained VT

Duration determines urgency:

A practical clinical concept is hemodynamic stability: a patient in VT who is alert, maintaining blood pressure, and has preserved peripheral perfusion is "stable VT" and can be treated with medications first. A patient in VT who is unconscious, hypotensive, or showing signs of cardiogenic shock is "unstable" and is treated with immediate electrical cardioversion, because drug therapy would lose critical time.

Back to Table of Contents

Wide Complex Tachycardia: VT vs SVT

A wide QRS tachycardia (QRS >120 ms at rate >100 bpm) has two main possibilities: ventricular tachycardia, or supraventricular tachycardia (SVT) with aberrant conduction (e.g., SVT conducting down a bundle branch block or accessory pathway). Getting this distinction right is critical — some SVT treatments (adenosine, verapamil) can cause cardiovascular collapse in VT.

The Brugada Criteria (1991)

Jose Brugada and colleagues described a four-step algorithm for wide complex tachycardia. A "yes" answer at any step diagnoses VT:

  1. Is there an absence of RS complexes in all precordial leads (V1–V6)?
  2. Is the R-to-S interval >100 ms in any precordial lead?
  3. Is there atrioventricular (AV) dissociation (P waves and QRS complexes firing independently)?
  4. Are there morphological criteria for VT in V1 and V6? (e.g., in left bundle branch block (LBBB)-pattern tachycardia: Q wave in V6; in right bundle branch block (RBBB)-pattern: monophasic R or Rr' in V1 + QS or rS in V6)

The Brugada criteria have ~98% sensitivity for VT when all four are systematically applied.

The Vereckei Algorithm (2008)

The Vereckei aVR algorithm uses only lead aVR — particularly useful when precordial leads are noisy. A "yes" at any step diagnoses VT:

  1. Is there an initial R wave in aVR?
  2. Is the initial r or q wave >40 ms in aVR?
  3. Is there a notch on the descending limb of a predominantly negative (QS or QR) complex in aVR?
  4. Is vi/vt ≤1? (ratio of initial to terminal deflection velocity)

A useful clinical rule: "If in doubt, treat as VT." VT is far more common than SVT-aberrancy in patients with structural heart disease; treating VT as SVT can be fatal, while the reverse mistake is rarely catastrophic.

Signs strongly suggesting VT rather than SVT: AV dissociation (independent P waves — "capture beats" and "fusion beats"), concordance (all precordial QRS complexes pointing the same direction), extreme axis deviation, and a QRS morphology that does not match any typical bundle branch block pattern.

Back to Table of Contents

Causes and Underlying Conditions

VT rarely arises in a normal heart. The substrate is nearly always some form of structural or electrical disease:

Back to Table of Contents

Acute Management: Stable and Unstable VT

The first decision in acute VT management is whether the patient is hemodynamically stable or unstable.

Unstable VT: DC Cardioversion

If the patient has altered consciousness, systolic blood pressure (BP) <80 mmHg, signs of pulmonary edema, or active chest pain from the arrhythmia: immediate synchronized direct-current (DC) cardioversion. Drug therapy is not used first, because it delays the shock; the energy used is 100–200 joules biphasic. If VT is pulseless (i.e., VF or pulseless VT), unsynchronized defibrillation is required — this is a cardiac arrest treated with cardiopulmonary resuscitation (CPR) and advanced cardiac life support (ACLS) protocols.

Stable Monomorphic VT: Antiarrhythmic Drugs

For hemodynamically stable, sustained monomorphic VT, two first-line intravenous antiarrhythmics are used in the United States:

Lidocaine intravenous is a third option, less commonly used than previously for VT because it is less effective, but still useful in acute ischemic VT where its sodium-channel block is well-suited to the ischemic mechanism.

Polymorphic VT and Torsades de Pointes

Polymorphic VT treatment depends on the underlying cause:

Back to Table of Contents

Long-Term Treatment: ICD and Catheter Ablation

Acute termination of VT does not address the underlying substrate. Long-term management prevents future episodes and sudden death.

Catheter Ablation for Recurrent Scar-Related VT

In patients with recurrent monomorphic VT from scar-related re-entry, catheter ablation maps the re-entry circuit and delivers radiofrequency energy to eliminate the critical isthmus within the scar. Modern three-dimensional electroanatomic mapping systems allow precise identification of scar borders, low-voltage zones, and late potentials.

In the SMASH-VT trial (2007; 128 patients with a past heart attack who received an implantable cardioverter-defibrillator (ICD) for VT or VF), adding catheter ablation cut appropriate ICD therapy from 33% to 12% (hazard ratio 0.35) and ICD shocks from 31% to 9% over about 22 months; deaths were 9% versus 17%, a difference that was not statistically significant. In the VTACH trial (2010; 107 patients with stable VT, a past heart attack and reduced ejection fraction), ablation before ICD implantation raised 2-year survival free from VT or VF from 29% to 47% (hazard ratio 0.61). The VANISH trial (2016; 259 patients with a past heart attack and an ICD who had VT despite antiarrhythmic drugs) found that ablation lowered the composite of death, VT storm, or appropriate ICD shock compared with escalated antiarrhythmic drug therapy (59.1% versus 68.5%, hazard ratio 0.72), with no significant difference in deaths. VANISH2 (2025) tested ablation as the first treatment: in 416 people with a past heart attack, an ICD and clinically significant VT, followed for a median of 4.3 years, the composite of death, VT storm, appropriate ICD shock or treated sustained VT occurred in 50.7% after catheter ablation versus 60.6% on sotalol or amiodarone (hazard ratio 0.75). Within 30 days of ablation, 2 patients (1.0%) died; among those on drug therapy, 1 patient (0.5%) died of lung toxicity attributed to the drug. Ablation does not replace an ICD but substantially reduces ICD shock burden and improves quality of life.

Antiarrhythmic Drugs for VT Suppression

Back to Table of Contents

ICD for Primary and Secondary Prevention

The ICD is the most effective therapy for preventing sudden cardiac death from VT/VF.

Secondary Prevention (after VT/VF arrest)

Patients who survive a cardiac arrest or sustained VT without a reversible cause have a high risk of recurrence. The AVID, CIDS, and CASH trials (late 1990s) established ICD superiority over antiarrhythmic drugs (mainly amiodarone) for secondary prevention, with a 20–31% relative reduction in total mortality.

Primary Prevention — MADIT-II

The MADIT-II trial (NEJM 2002, N=1,232) enrolled patients with prior myocardial infarction and EF ≤30% with no history of sustained VT. Prophylactic ICD implantation reduced all-cause mortality by 31% (hazard ratio (HR) 0.69, p=0.016) compared with conventional medical therapy over an average of 20 months: 19.8% of patients died in the conventional-therapy group versus 14.2% in the defibrillator group. This trial established the principle that patients do not need to have had VT to benefit from an ICD.

Primary Prevention — SCD-HeFT

The SCD-HeFT trial (NEJM 2005, N=2,521) enrolled patients with EF ≤35% from both ischemic and non-ischemic cardiomyopathy, all in New York Heart Association (NYHA) Class II–III. ICD therapy reduced all-cause mortality by 23% (hazard ratio 0.77, p=0.007) vs placebo over a median of 45.5 months: 244 deaths (29%) in the placebo group, 240 (28%) in the amiodarone group and 182 (22%) in the ICD group, an absolute decrease in mortality of 7.2 percentage points after five years. Amiodarone showed no mortality benefit vs placebo. Results did not vary by ischemic versus non-ischemic cause but did vary by NYHA class. SCD-HeFT extended ICD benefit to non-ischemic cardiomyopathy and confirmed the EF ≤35% threshold used in current guidelines.

Current ICD Indications (simplified)

Back to Table of Contents

Special Syndromes: Long-QT, Brugada, and CPVT

Congenital Long-QT Syndrome (LQTS)

Congenital LQTS is caused by mutations in cardiac ion channels that delay ventricular repolarization. QTc >460 ms in women and >440 ms in men raises suspicion; QTc >500 ms is high risk. The three commonest subtypes are LQT1 (KCNQ1, triggered by exercise/swimming), LQT2 (KCNH2, triggered by sudden sounds/startle), and LQT3 (SCN5A, triggered at rest/sleep). Treatment: beta-blockers for LQT1 and LQT2; mexiletine ± beta-blockers for LQT3; left cardiac sympathetic denervation for drug-refractory cases.

Brugada Syndrome

Brugada syndrome is caused by loss-of-function mutations in SCN5A (in ~20% of cases; others unknown) producing a characteristic Type 1 Brugada electrocardiogram pattern (coved ST elevation ≥2 mm in V1–V2). Risk stratification is imperfect; patients with prior cardiac arrest or spontaneous Type 1 pattern are highest risk. ICD is the only proven therapy for high-risk Brugada; quinidine may reduce VF burden. Fever can unmask the pattern and trigger arrhythmias, which is why fever is treated promptly in people with Brugada syndrome.

Catecholaminergic Polymorphic VT (CPVT)

CPVT is caused by mutations (RYR2, CASQ2) that lead to pathological calcium release from the sarcoplasmic reticulum during adrenergic stimulation. Exercise provokes bidirectional or polymorphic VT in an otherwise normal heart. First-line therapy: nadolol (preferred over metoprolol for its non-selective beta-blockade). Flecainide reduces calcium leak directly and is added if beta-blockers alone are insufficient. In the first randomized trial of flecainide in CPVT (2017; 14 patients on maximally tolerated beta-blockers, 13 completed), adding flecainide gave complete suppression of exercise-induced ventricular arrhythmia in 11 of 13 patients (85%), and adverse events did not differ from placebo. Exercise restriction is part of standard CPVT management; an ICD is used in high-risk patients, but inappropriate shocks can trigger catecholamine surges that worsen VT, so device programming is done with particular care.

Back to Table of Contents

Key Research Papers

The following citations are from published peer-reviewed literature on ventricular tachycardia. PubMed links open the specific article.

  1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–883. (MADIT-II) — doi:10.1056/NEJMoa013474 · PubMed PMID: 11907286
  2. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–237. (SCD-HeFT) — doi:10.1056/NEJMoa043399 · PubMed PMID: 15659722
  3. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016;375(2):111–121. (VANISH) — doi:10.1056/NEJMoa1513614 · PubMed PMID: 27149033
  4. Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E, et al.; VTACH study group. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375(9708):31–40. — doi:10.1016/S0140-6736(09)61755-4 · PubMed PMID: 20109864
  5. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357(26):2657–2665. (SMASH-VT) — doi:10.1056/NEJMoa065457 · PubMed PMID: 18160685
  6. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991;83(5):1649–1659. — doi:10.1161/01.cir.83.5.1649 · PubMed PMID: 2022022
  7. Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm. 2008;5(1):89–98. — doi:10.1016/j.hrthm.2007.09.020 · PubMed PMID: 18180024
  8. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576–1583. — doi:10.1056/NEJM199711273372202 · PubMed PMID: 9411221
  9. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348(19):1866–1874. — doi:10.1056/NEJMoa022147 · PubMed PMID: 12736279
  10. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, et al. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. JAMA Cardiol. 2017;2(7):759–766. — doi:10.1001/jamacardio.2017.1320 · PubMed PMID: 28492868
  11. deSouza IS, Martindale JL, Sinert R. Antidysrhythmic drug therapy for the termination of stable, monomorphic ventricular tachycardia: a systematic review. Emerg Med J. 2015;32(2):161–167. — doi:10.1136/emermed-2013-202973 · PubMed PMID: 24042252
  12. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation. 2018;138(13):e272–e391. — doi:10.1161/CIR.0000000000000549 · PubMed PMID: 29084731
  13. Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, Almendral J; PROCAMIO Study Investigators. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017;38(17):1329–1335. — doi:10.1093/eurheartj/ehw230 · PubMed PMID: 27354046
  14. Sapp JL, Tang ASL, Parkash R, Stevenson WG, Healey JS, Gula LJ, et al.; VANISH2 Study Team. Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. N Engl J Med. 2025;392(8):737–747. (VANISH2) — doi:10.1056/NEJMoa2409501 · PubMed PMID: 39555820
  15. U.S. National Library of Medicine, DailyMed. Amiodarone hydrochloride injection, prescribing information, section 5.1 Hypotension. — DailyMed label

Back to Table of Contents

Connections

Back to Table of Contents